Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
KPV vs Vesugen
An educational, source-based comparison of KPV and Vesugen — how each peptide works, what it's researched for, and what to know before going deeper.
The C-terminal tripeptide (Lys-Pro-Val) of α-MSH. Research suggests anti-inflammatory effects via melanocortin pathways and intracellular NF-κB modulation — without the pigmentation effects of full-length α-MSH.
- Inflammatory bowel disease models
- Atopic dermatitis (topical research)
- Mast cell stabilization
- • Not FDA-approved.
- • Most evidence is preclinical.
A synthetic tripeptide (Lys-Glu-Asp) in the Khavinson bioregulator family. Research indicates modulation of endothelial cell function and vascular wall gene expression, supporting vascular tone and microcirculation.
- Vascular endothelial function
- Microcirculation in aging
- Peripheral vascular disorders
- • Russian-origin research; independent replication limited.
- • Not FDA-approved.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| KPV | KPV reduces colonic inflammation in IBD models | Gastroenterology | 2009 | Oral KPV nanoparticles reduced inflammatory markers in mouse colitis. |
| Vesugen | Vesugen and vascular endothelial gene expression | Bulletin of Experimental Biology and Medicine | 2014 | Enhanced endothelial nitric oxide synthase expression in vascular tissue models. |
Side-effect & safety grid
- Not FDA-approved.
- Most evidence is preclinical.
- Russian-origin research; independent replication limited.
- Not FDA-approved.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
KPV vs Vesugen — Key differences
- Class: KPV is classified as Gastrointestinal · Anti-inflammatory, while Vesugen is Vascular · Bioregulator.
- Primary research focus: KPV — inflammatory bowel disease models; Vesugen — vascular endothelial function.
- Tag: Gut · Anti-inflammatory vs Vascular · Bioregulator.